Calreticulin Antibody (1G6A7) - BSA Free

Calreticulin, also called CALR, is an endoplasmic reticulum (ER) protein that functions as a calcium (Ca2+) buffering molecular chaperone (1-3). Together with calnexin and ERp57, calreticulin has a critical role in protein folding and quality control of newly synthesized glycoproteins (1-3). Calreticulin has many diverse functions beyond Ca2+ binding, including cell adhesion, lectin binding, apoptosis, nuclear transport, antigen presentation, and immune response (1-3). Specifically, calreticulin is part of the peptide-loading complex that resides on the ER membrane and is responsible for antigen loading onto MHC class I molecules (1-3). Calreticulin protein has a theoretical molecular weight of 46 kDa and is 417 amino acids (aa) in length (1-3). The protein has three main domains: the N-terminal lectin-like domain, the proline-rich P-domain, and the acidic C-domain which is followed by an ER-retention KDEL signal sequence (1-3).

Given its role in multiple biological processes, it makes sense that calreticulin is implicated in both healthy and disease states. Studies have found that calreticulin mutations were present in patients with myeloproliferative neoplasms (MFN) and essential thrombocythaemia (ET) (4). Calreticulin expression is typically upregulated in most cancer lines, however it is downregulated in some tissues including cervical carcinomas, prostate cancer, and human colon adenocarcinoma (3). High expression of calreticulin on cancer cells is related to tumor cell phagocytosis and is often correlated with, and counteracted by, elevated CD47 expression to prevent cancer cell phagocytosis (3). Calreticulin mutations can serve as a major diagnostic biomarker for MFN and ET and additionally the calreticulin gene may be a potential target for cancer therapeutics (3,4).

References

1. Michalak, M., Groenendyk, J., Szabo, E., Gold, L. I., & Opas, M. (2009). Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. The Biochemical Journal. https://doi.org/10.1042/BJ20081847

2. Fucikova, J., Spisek, R., Kroemer, G., & Galluzzi, L. (2021). Calreticulin and cancer. Cell Research. https://doi.org/10.1038/s41422-020-0383-9

3. Sun, J., Mu, H., Dai, K., & Yi, L. (2017). Calreticulin: a potential anti-cancer therapeutic target. Die Pharmazie. https://doi.org/10.1691/ph.2017.7031

4. Prins, D., Gonzalez Arias, C., Klampfl, T., Grinfeld, J., & Green, A. R. (2020). Mutant Calreticulin in the Myeloproliferative Neoplasms. HemaSphere. https://doi.org/10.1097/HS9.0000000000000333

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 7 applications: ELISA, FLOW, Flow Cytometry, ICC/IF, IHC-Fr, In vitro, In vivo assay.

Showing Publications 1 - 10 of 21. Show All 21 Publications. Collapse Publications.

Publications using NBP1-47518	Applications	Species
Mu L, Qi L, Long H et al. Photothermal Fibrous Chitosan/Polydopamine Sponge for Intraoperative Hemostasis and Prevention of Tumor Recurrence in Hepatocellular Carcinoma Resection Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023-11-29 [PMID: 38029340] (FLOW)	FLOW
Yeh YT, Sona C, Yan X et al. Restoration of PITPNA in Type 2 diabetic human islets reverses pancreatic beta-cell dysfunction Nature Communications 2023-07-17 [PMID: 37460527] (ELISA, In vivo assay)	ELISA, In vivo assay
Gu Z, Hao Y, Schomann T et al. Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation Journal of controlled release : official journal of the Controlled Release Society 2023-04-21 [PMID: 37030544] (ICC/IF, Mouse)	ICC/IF	Mouse
Gu Z, Da Silva CG, Hao Y et al. Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer Journal of controlled release : official journal of the Controlled Release Society 2022-12-09 [PMID: 36460179] (ICC/IF, Mouse)	ICC/IF	Mouse
Kim S, Choe M, Oh J, Kim J Centrosome de-clustering of cancer cells induces cGAS-STING-mediated innate immunity of tumor-associated tumor cells in response to irradiation Biochemical and Biophysical Research Communications 2022-10-01 [PMID: 36343487] (FLOW, Human)	FLOW	Human
Kim SS, Doherty C, Moghe M Et al. Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity Cancers (Basel) 2022-10-27 [PMID: 36291878] (FLOW, Human) Details: Citation using the Alexa Fluor 405 version of this antibody.	FLOW	Human
Chang L, Chin Y, Wu P et al. Polymeric nano-formulation of spectrum selective RTK inhibitor strengthens anti-cancer effects via immune remodeling by endoplasmic reticulum stress-modulating mitochondrial metabolism Nano Today 2024-02-01 (IHC-Fr, Mouse)	IHC-Fr	Mouse
Wang H, Huang Q, Zhang Z Et al. Transient post-operative overexpression of CXCR2 on monocytes of traumatic brain injury patients drives monocyte chemotaxis toward cerebrospinal fluid and enhances monocyte-mediated immunogenic cell death of neurons in vitro J Neuroinflammation 2022-06-29 [PMID: 35768823] (FLOW, Human) Details: Citation using the Allophycocyanin version of this antibody.	FLOW	Human
Bian Q, Huang L, Xu Y et al. A Facile Low-Dose Photosensitizer-Incorporated Dissolving Microneedles-Based Composite System for Eliciting Antitumor Immunity and the Abscopal Effect ACS nano 2021-12-28 [PMID: 34859990]
Li Y, Han W, He C et al. Nanoscale Coordination Polymers for Combined Chemotherapy and Photodynamic Therapy of Metastatic Cancer Bioconjug Chem 2021-10-04 [PMID: 34607430] Details: Citation using the Alexa Fluor 488 format of this antibody.
Montes de Oca R, Alavi AS, Vitali N et al. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo Molecular Cancer Therapeutics 2021-10-01 [PMID: 34253590] (Flow Cytometry)	Flow Cytometry
Bekeschus S, Liebelt G, Menz J et al. Tumor cell metabolism correlates with resistance to gas plasma treatment: The evaluation of three dogmas Free radical biology & medicine 2021-03-09 [PMID: 33711420]
Ling X, Han W, Jiang X, et al. Intestinal TMEM16A control luminal chloride secretion in a NHERF1 dependent manner Biomaterials 2021-01-01 [PMID: 33561626]
Go EJ, Yang H, Chon HJ et al. Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy Cancers 2020-10-26 [PMID: 33114476] (In vitro, Mouse)	In vitro	Mouse
Kim J, Sestito L, Im S et al. Poly(cyclodextrin)-Polydrug Nanocomplexes as Synthetic Oncolytic Virus for Locoregional Melanoma Chemoimmunotherapy Adv Funct Mater 2020-10-19 [PMID: 33071710]
Yang J, Wang T, Zhao L et al. Gold/alpha-lactalbumin nanoprobes for the imaging and treatment of breast cancer Nat Biomed Eng 2020-07-01 [PMID: 32661307]
Hu C, Lei T, Wang Y et al. Phagocyte-membrane-coated and laser-responsive nanoparticles control primary and metastatic cancer by inducing anti-tumor immunity Biomaterials 2020-06-07 [PMID: 32554131] (FLOW, Mouse)	FLOW	Mouse
Bekeschus S, Clemen R, Niebner F et al. Medical Gas Plasma Jet Technology Targets Murine Melanoma in an Immunogenic Fashion Adv. Sci. 2020-03-30 [PMID: 32440479]
Kim DH, Seo J, Na K pH-Sensitive Carbon Dots for Enhancing Photomediated Antitumor Immunity Immunity Mol. Pharm. 2020-05-22 [PMID: 32407125] Details: Citation using the Alexa Fluor 488 format of this antibody.
Freund E, Liedtke KR, Miebach L et al. Identification of Two Kinase Inhibitors with Synergistic Toxicity with Low-Dose Hydrogen Peroxide in Colorectal Cancer Cells in vitro Cancers (Basel). [PMID: 31906582] (FLOW, Mouse)	FLOW	Mouse
Kim S, Harford J, Moghe M et al. Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor OncoImmunology 2018 Jun 12 [PMID: 30288347] (Flow, Mouse) Oncoimmunology. [PMID: 30288347] (FLOW, Mouse)	FLOW	Mouse
Show All 21 Publications. Collapse Publications.

Array NBP1-47518

• Calreticulin Antibodies
• Calreticulin ELISA Kits
• Calreticulin Lysate
• Calreticulin Protein